Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
4 hedge funds and large institutions have $109K invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 14 closing their positions.
78% less funds holding
Funds holding: 18 → 4 (-14)
96% less capital invested
Capital invested by funds: $2.5M → $109K (-$2.4M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 14
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.32M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$260K |
| 3 |
AFG
American Financial Group
Cincinnati,
Ohio
|
-$178K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$100K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$93.3K |
ELOX Hedge Fund Activity: Q4 2023 in Review
4 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q4 2023, worth a combined $109K — down 96% from $2.5M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ELOX and 0 opened new positions — a net loss of 14 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Armistice Capital, exiting entirely with an estimated $1.32M sold.
- 4 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q4 2023, down from 18 in Q3 2023.
- Funds reported $109K of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q4 2023, down 96% quarter-over-quarter.
- 0 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q4 2023 and 14 closed out, a net change of -14 holders.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q4 2023 was Armistice Capital, an estimated $1.32M sold.
Based on aggregated 13F filings for Q4 2023.